colestipol colestipol colestipol (trade names colestid, cholestabyl) is a bile acid sequestrant used to lower blood cholesterol, specifically low-density lipoprotein (ldl). it is also used to reduce stool volume and frequency, and in the treatment of chronic diarrhea. colestipolclinical datatrade namescolestid, cholestabylahfs/drugs.commonographmedlineplusa682157routes ofadministrationoral (suspension or tablets)atc codec10ac02 (who) legal statuslegal status us: ℞-only pharmacokinetic databioavailabilitynoneexcretionfaeces, in complex with bile acidsidentifiers iupac name copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane cas number26658-42-4 n 37296-80-3 (hcl)pubchem cid62816drugbankdb00375 ychemspidernoneuniik50n755924keggc06925 ychemblchembl1201678 ycomptox dashboard (epa)dtxsid00965206 dtxsid901009549, dtxsid00965206 echa infocard100.123.044 chemical and physical dataformula(c4h10n3)m(c3h6o)n ny (what is this?) (verify) like cholestyramine, colestipol works in the gut by trapping bile acids and preventing them from being reabsorbed. this leads to decreased enterohepatic recirculation of bile acids, increased synthesis of new bile acids by the liver from cholesterol, decreased liver cholesterol, increased ldl receptor expression, and decreasing ldl in blood. side effects the following notable side effects may occur: gastrointestinal tract disturbances, especially (mild, occasionally severe) constipation sometimes increase in vldl and triglyceride synthesis interactions colestipol can bind to a number of drugs and nutrients in the gut and inhibit or delay their absorption. such substances include: thiazide diuretics, furosemide gemfibrozil benzylpenicillin, tetracycline digoxin lipid-soluble vitamins (a, d, e, k) contraindications colestipol is contraindicated in hypertriglyceridemia (high level of triglycerides in the blood). chemistry colestipol is a copolymer of diethylenetriamine (deta) —or tetraethylenepentamine according to some sources— and epichlorohydrin. the structure drawing (top right) shows the deta moieties in blue and the epichlorohydrin moieties in red. alternative chemical structure, with tetraethylenepentamine instead of diethylenetriamine; formula (c8h18n5)m(c3h6o)n the constituent detathe constituents tetraethylenepentamine (top) and epichlorohydrin (bottom) notes and references handelsman y (may 2011). "role of bile acid sequestrants in the treatment of type 2 diabetes". diabetes care. 34 suppl 2 (suppl 2): s244-50. doi:10.2337/dc11-s237. pmc 3632187. pmid 21525463. drugs.com: colestipol hydrochloride "colestipol (colestid)". medicinenet. mutschler e, schäfer-korting m (2001). arzneimittelwirkungen (in german) (8th ed.). stuttgart: wissenschaftliche verlagsgesellschaft. p. 523. isbn 3-8047-1763-2. clinical pharmacology: colestipol structure beth israel deaconess medical center & care group: colestipol structure archived 2010-12-29 at the wayback machine haberfeld h, ed. (2009). austria-codex (in german) (2009/2010 ed.). vienna: österreichischer apothekerverlag. isbn 978-3-85200-196-8. steinhilber d, schubert-zsilavecz m, roth hj (2005). medizinische chemie (in german). stuttgart: deutscher apotheker verlag. p. 433. isbn 3-7692-3483-9. lipid-modifying agents (c10)gi tractcholesterol absorption inhibitors, npc1l1 ezetimibe sch-48461 bile acid sequestrants/resins (ldl) colesevelam colestilan colestipol colestyramine colextran liverstatins (hmg-coa reductase, ldl) atorvastatin cerivastatin‡ fluvastatin lovastatin mevastatin pitavastatin pravastatin rosuvastatin simvastatin# niacin and derivatives (hdl and ldl) acipimox aluminium nicotinate niacin niceritrol nicofuranose nicotinyl alcohol mttp inhibitors (vldl) dirlotapide lomitapide mitratapide atp citrate lyase inhibitors (ldl) bempedoic acid blood vesselsfibrates (ppar) aluminium clofibrate bezafibrate choline fenofibrate ciprofibrate clinofibrate clofibrate‡ clofibride etofibrate fenofibrate gemfibrozil nafenopin pemafibrate ronifibrate simfibrate cetp inhibitors (hdl) anacetrapib† dalcetrapib§ evacetrapib§ obicetrapib† torcetrapib§ pcsk9 inhibitors (ldl) alirocumab bococizumab evolocumab combinations amlodipine/atorvastatin bempedoic acid/ezetimibe ezetimibe/atorvastatin ezetimibe/rosuvastatin ezetimibe/simvastatin fenofibrate/pravastatin fenofibrate/simvastatin niacin/laropiprant niacin/lovastatin niacin/simvastatin other alipogene tiparvovec azacosterol azalanstat benfluorex‡ darapladib§ dextrothyroxine‡ inclisiran lapaquistat§ magnesium pyridoxal 5-phosphate glutamate meglutol mipomersen omega-3-triglycerides policosanol probucol tiadenol triparanol‡ volanesorsen #who-em ‡withdrawn from market clinical trials: †phase iii §never to phase iii this article is issued from wikipedia. the text is licensed under creative commons - attribution - sharealike. additional terms may apply for the media files.